Loading…
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-14M | $-12M | $-9M | -14.9% | - | - |
| 2024 | $0M | $-3M | $-3M | $-2M | -50.6% | - | - |
| 2023 | $0M | $-7M | $-7M | $-7M | -111.7% | - | - |
| 2022 | $0M | $-15M | $-15M | $-14M | -141.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 14.98 | 7.39 | 2.82 | 13.94 |
| Operating Income | -14.98 | -7.39 | -2.82 | -13.94 |
| EBITDA | -14.97 | -7.31 | -2.75 | -13.86 |
| EBIT | -14.98 | -7.39 | -2.82 | -13.94 |
| Pretax Income | -14.96 | -7.37 | -2.80 | -12.23 |
| Net Income | -14.96 | -7.37 | -2.80 | -12.23 |
| Net Income Common Stockholders | -14.96 | -7.37 | -2.80 | -12.23 |
| Total Expenses | 14.98 | 7.39 | 2.82 | 13.94 |
| Interest Income | 0 | 0 | 0.03 | 1.52 |
| Research And Development | 12.18 | 5 | 1.18 | 11.08 |
| Selling General And Administration | 2.55 | 2.20 | 1.45 | 2.57 |
| Normalized EBITDA | -14.98 | -7.33 | -2.74 | -14.05 |
| Normalized Income | -14.98 | -7.39 | -2.79 | -12.42 |
| Basic EPS | -6.06 | -1.98 | -0.65 | -1.78 |
| Diluted EPS | -6.06 | -1.98 | -0.65 | -1.78 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.01 | 0.01 | -0.01 | 0.19 |
| Total Unusual Items Excluding Goodwill | 0.01 | 0.01 | -0.01 | 0.19 |
| Net Income From Continuing Operation Net Minority Interest | -14.96 | -7.37 | -2.80 | -12.23 |
| Reconciled Depreciation | 0.01 | 0.07 | 0.07 | 0.08 |
| Net Interest Income | 0 | 0 | 0.03 | 1.52 |
| Net Income From Continuing And Discontinued Operation | -14.96 | -7.37 | -2.80 | -12.23 |
| Diluted Average Shares | 2.47 | 3.72 | 4.31 | 6.88 |
| Basic Average Shares | 2.47 | 3.72 | 4.31 | 6.88 |
| Diluted NI Availto Com Stockholders | -14.96 | -7.37 | -2.80 | -12.23 |
| Net Income Including Noncontrolling Interests | -14.96 | -7.37 | -2.80 | -12.23 |
| Net Income Continuous Operations | -14.96 | -7.37 | -2.80 | -12.23 |
| Other Income Expense | 0.01 | 0.01 | -0.01 | 0.19 |
| Other Non Operating Income Expenses | -0.24 | 0 | 0 | 0 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0.01 | 0.01 | -0.01 | 0.19 |
| Net Non Operating Interest Income Expense | 0 | 0 | 0.03 | 1.52 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0 | 0 | 0.03 | 1.52 |
| Other Operating Expenses | 0.24 | 0.19 | 0.20 | 0.29 |
| Selling And Marketing Expense | 0.55 | 0.12 | 0.04 | 0.43 |
| General And Administrative Expense | 2 | 2.08 | 1.40 | 2.14 |
| Other Gand A | 1.90 | 0.92 | 0.91 | 1.64 |
| Salaries And Wages | 0.10 | 1.16 | 0.49 | 0.50 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bright Minds Biosciences Inc.this co. | DRUG | $872M | - | 10.63 | -14.9% | - |
| Sana Biotechnology, Inc. | SANA | $877M | - | 5.39 | -151.8% | -4.57 |
| LB Pharmaceuticals Inc | LBRX | $877M | - | 2.57 | -8.4% | -20.06 |
| Talkspace, Inc. | TALK | $869M | 129.75 | 7.39 | 6.7% | 128.51 |
| SELLAS Life Sciences Group, Inc. | SLS | $862M |
| - |
| 10.09 |
| -37.9% |
| - |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 | -16.57 | -11.5% | 19.49 |
| Peer Median | - | 129.75 | 3.26 | -11.7% | -4.57 | |